#Obesity #Type2diabetes #EliLilly #Foundayo #orforglipron #regulatoryapproval #UK #MHRA #pharmanews #MarketAccess #oralGLP1agonist #weightmanagement #weightloss #weightmaintenance #GLP1receptoragonists #privateprescription #NHSReimbursement #NICE #cardiometabolicmedicine
zurl.co/o9OI7
zurl.co/o9OI7
UK is first European country to approve Lilly's Foundayo
Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.
zurl.co
August 11, 2026 at 2:24 PM
#EliLilly has announced that #orforglipron, its #oralGLP1 receptor agonist, is now available to be prescribed for eligible adults via #privateprescription following its approval by the #MHRA.
pharmaphorum.com/news/uk-mhra...
pharmaphorum.com/news/uk-mhra...
UK MHRA authorises orforglipron private prescription
Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.
pharmaphorum.com
August 24, 2026 at 8:42 AM
#EliLilly has announced that #orforglipron, its #oralGLP1 receptor agonist, is now available to be prescribed for eligible adults via #privateprescription following its approval by the #MHRA.
pharmaphorum.com/news/uk-mhra...
pharmaphorum.com/news/uk-mhra...